Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Method for building allergen-specific immunotherapy asthma model

A technology for immunotherapy and establishment of methods, which is applied in the direction of allergen antigen components, pharmaceutical formulas, antibody medical components, etc., which can solve the problems of long research cycle, incomplete clarification of the exact mechanism, and inability to obtain data well, so as to shorten the The effect of the study cycle

Inactive Publication Date: 2018-03-20
THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, AIT has been used clinically in the treatment of allergic asthma, and is recommended by the guidelines as the only effective preventive treatment for the etiology of asthma. Current studies believe that regulatory T cells (regulatory T cells, Treg) play an important role in the treatment mechanism of AIT. However, its exact mechanism has not been fully elucidated. Therefore, it is of great significance to establish an animal model of AIT for the treatment of asthma to study the therapeutic dose, course of treatment and pathogenesis of allergens.
[0003] The traditional AIT treatment asthma model is similar to the process of clinical immunotherapy for asthma. It is necessary to establish an asthma (asthma symptoms through sensitization-challenge) model, and then simulate the daily increase of the dose of allergens used in clinical practice for subcutaneous injection or aerosol inhalation, but The research period is long, and some data (including lung tissue inflammation, accuracy of airway hyperresponsiveness, etc.) cannot be obtained well. Establishing an animal model that takes a short time and has a similar effect to traditional AIT in treating asthma is crucial to solving these problems have important meaning

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for building allergen-specific immunotherapy asthma model
  • Method for building allergen-specific immunotherapy asthma model
  • Method for building allergen-specific immunotherapy asthma model

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0017] The preferred embodiments of the present invention will be described in detail below with reference to the accompanying drawings.

[0018] In this example, three groups of allergen-specific immunotherapy model group, asthma group, and normal control group were set up for comparison, and the results were verified from airway hyperresponsiveness, lung tissue inflammation, serum IgE, Th2 cell inflammatory factors, and Treg expression. The invention achieves the same therapeutic effect as the traditional immunotherapy model.

[0019] 1. Animal selection,

[0020] Clean-grade BALB / c mice, 6-8 weeks old, female, weighing 16-20 g, were fed non-allergenic feed. They were randomly divided into 3 groups by digital table method: allergen-specific immunotherapy model group, asthma group, and normal control group.

[0021] 2. Model building steps,

[0022] 2.1 Establish the allergen-specific immunotherapy model of this example,

[0023] In the sensitization stage, OVA 10μg and A...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a method for building an allergen-specific immunotherapy asthma model and belongs to the biotechnology field. The method comprises the steps of firstly sensitizing, then carrying out large dose allergen immunotherapy and finally stimulating and producing asthma symptoms. The method provided by the invention can realize an allergen immunotherapy asthma model with the same effect with the traditional therapy model (sensitization-stimulation-allergen immunotherapy), and a research period for building the asthma model is shortened at the same time.

Description

technical field [0001] The invention belongs to the field of biotechnology, and relates to a method for establishing an asthma model for allergen-specific immunotherapy. Background technique [0002] Allergen-specific immunotherapy (Allergen immunotherapy, AIT) is to gradually increase the dose of allergen extracts to repeatedly expose allergic patients to improve the patient's tolerance to such allergens, thereby controlling or reducing allergic symptoms a method of treatment. AIT is currently the only treatment that may alter the natural course of allergic disease. At present, AIT has been used clinically in the treatment of allergic asthma, and is recommended by the guidelines as the only effective preventive treatment for the etiology of asthma. Current studies believe that regulatory T cells (regulatory T cells, Treg) play an important role in the treatment mechanism of AIT. However, its exact mechanism has not been fully elucidated. Therefore, it is of great signific...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/35A61K39/39
Inventor 廖伟胡琦钟世民范文婷曾靖胡影
Owner THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com